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Epstein-Barr virus (EBV) is a ubiquitous human gammaherpesvirus that 
establishes a latency reservoir in B cells. EBV is the causative agent for several 
epithelial and B cell cancers mostly in immunocompromised patients. In order to 
maintain a reservoir of EBV over an infected persons lifetime, EBV must 
periodically reactivate from latency and enter lytic replication to produce 
infectious virions, which go on to infect new cells. This can happen 
spontaneously or by stimulus, such as activating the B cell receptor (BCR) 
pathway. While the importance of BCR signaling in relation to EBV activation has 
not been described in-vivo, B cell receptor signaling may have an impact on EBV 
activation in patients. Some B cell malignancies are treated with drugs that inhibit 
the BCR pathway. Thus it is conceivable that these drugs might affect the viral 
reservoir maintained by basal B cell receptor signaling. 
Here, we show that a group of BCR signaling pathway kinase inihibitors 
used to treat hematologic malignancies, ibrutinib, idelalisib, and dasatinib, block 
BCR-mediated EBV lytic induction at clinically relevant doses. siRNA 
experiments where the targets of these drugs were depleted resulted in the 
inability of these drugs to block BCR-mediated EBV induction. We found that 
these drugs specifically block phosphorylation of their targets in the presence of 
BCR stimulation. Other lytic inducers were tested in the presence of these drugs, 
and none of the drugs were able to block EBV induction by the other inducers.  
Thus we believe that blocking BCR-mediated lytic induction by ibrutinib, idelalisib 
and dasatinib is specific and clinically relevant. 
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In this work, we also confirmed that the immunosuppressive drugs 
cyclosporine and tacrolimus inhibit BCR-mediated lytic induction, while 
rapamycin does not. Rapamycin targets mTOR, which is downstream but still 
part of the BCR pathway. Treatment of cells with torin2, which inhibits both 
mTORC1 and mTORC2 prior to EBV induction via the BCR pathway shows that 
mTORC2 contributes to BCR-mediated lytic induction and that FKBP12 binding 
alone is not adequate to block activation.  
Additionally, we show that BCR signaling can activate EBV in freshly 
isolated B cells from peripheral blood mononuclear cells (PBMC) and that this 
activation can be inhibited by ibrutinib or idelalisib.   
Taken together, this work shows that ibrutinib, idelalisib and dasatinib 
block BCR-mediated lytic induction in a specific manner and at clinically relevant 
doses. While rapamycin does not block BCR-mediated lytic induction on its own, 
it was determined that mTORC2 plays a role in the BCR pathway and contributes 
to BCR-mediated lytic activation of EBV. We found that we were able to replicate 
this system in patient-derived PBMCs, thus suggesting that this system may be 
relevant in humans and could play a role in future studies on EBV maintenance 
in the context of long-term treatment by BCR pathway inhibitors. 
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Epstein-Barr virus (EBV), otherwise known as humanherpesvirus 4 (HHV-
4), is one of eight human herpesviruses. EBV infects most adults worldwide, and 
an EBV reservoir is present in an individual for life after initial infection (1). EBV 
plays a role in numerous diseases, such as infectious mononucleosis and 
several forms of cancer, both epithelial (nasopharyngeal carcinoma, gastric 
cancer) and B cell-related (Hodgkin’s lymphoma, Burkitt’s lymphoma) (2-4). EBV 
infection is usually symptom-free when contracted while young, but if contracted 
during teenage or later years, infectious mononucleosis typically presents (5). In 
immunocompromised patients, such as those suffering from AIDS or having 
recently undergone transplantation and receiving immumosuppressive drugs, 
EBV can transform cells and result in cancer (6). Such cancers often regress 
when treatment by immunosuppressive drugs is withdrawn. 
 EBV can exist in either a latent or a lytic replication state. Latent 
replication results in viral genome replication but no virion production, whereas 
lytic replication results in infectious virion production and subsequent infection of 
new cells (7). 
Virion structure and genome 
EBV infection can result in newly produced infectious EBV virions. The 
viral DNA is surrounded by a nucoelcapsid and tegument. The EBV genome is 
~173,000 bases and encodes for approximately 80 protein gene products (8). 
Finally, a lipid envelope which is embedded with glycoproteins, which serve as a 
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membrane and the glycoproteins essential for EBV attachment and subsequent 
infection of cells and viral tropism (9).  
Viral entry into cells 
EBV infects primarily B and epithelial cells. Four glycoproteins – gB, the 
gL/gH heterodimer, and gp42 – are required and mediate EBV entry into B cells 
(10). The gL/gH heterodimer and gp42 form a three-part complex, which is 
necessary for B cell fusion. gH and gL form heterodimer complexes, which 
mediate EBV entry into epithelial cells, along with gp350 and an additional 
heterodimer complex consisting of BMRF2 and BDLF2 (11-15). In B cells, human 
leukocyte antigen (HLA) class II molecules interact with and degrade three-part 
complexes in the endoplasmic reticulum, thus EBV produced in B cells contains 
the heterodimer complex composed of gH and gL, but not the gL/gH/gp42 three-
part complex. HLA class II molecules are not present in epithelial cells, resulting 
in EBV produced in epithelial cells incorporating more gL/gH/gp42 three-part 
complexes (16). Therefore, EBV produced in B cells is more efficient at infecting 
epithelial cells, whereas EBV produced in epithelial cells is more efficient at 
infecting B cells. Viruses without gp42 can bind B cells, but do not enter cells and 
are replication defective (17).  
The mechanism by which EBV enters B cells differs from the mechanism 
by which EBV enters epithelial cells. In B cells, the EBV glycoprotein gp350 binds 
CD21 on the cell surface, and g42 interacts with major histocompatibility complex 
(MHC) class II molecules (10). This results in fusion between the viral envelope 
and cell membrane, and EBV enters the cell (18).  
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Infection of epithelial cells by EBV requires the viral protein BMRF-2 and 
cellular beta-1 integrins. During infection, the gH/gB complex interacts with 
cellular integrins (10, 19). Once this occurs, fusion of the viral envelope and 
cellular membrane is possible. In B and epithelial cells, the viral envelope 
disassociates after the virus enters a host cell.  
Lytic replication 
During EBV lytic replication cycle, infectious virions are produced. Lytic 
replication can occur in both B and epithelial cells. In B cells, lytic replication 
occurs after a latent phase of replication, whereas in epithelial cells, lytic 
replication typically occurs directly following infection (20). Lytic replication results 
in linear viral genome becoming packaged into capsids. This is in contrast to 
latency, where the viral genome persists in a circularized state as an episome. 
Lytic genes are expressed in stages classified as immediate-early, early and late. 
Immediate-early genes tend to act as transactivators, such as Zta (Z, Zebra, 
BZLF1, Zebra transactivator), enhancing the expression of later genes. Early 
genes have a wider array of functions, such as DNA replication, metabolism and 
immune system evasion (blockade of antigen expression). Late lytic genes have 
mostly structural roles, such as capsid and virion structural components (21). 
BCRF1, a late lytic gene, helps the virus evade the immune system. EBV buds 
from cells, and lytic infection often leads to cell death.  
Latent replication 
Latent replication does not result in virion production. During latency, the 
viral genome circularizes and is maintained as an episome through tethering to 
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host cell chromosomes by EBNA1 (22). During latency, only small subsets of 
EBV genes are expressed, and these subsets can be grouped into latency type I, 
II and III. The genes expressed and latency type is dependent upon the host cell 
and stage of infection. 
Table 1. EBV Latency genes organized by latency type. 
Gene EBNA1 EBNA2 EBNA3A EBNA3B EBNA3C EBNALP LMP1 LMP2A LMP2B EBER 
Type Protein Protein Protein Protein Protein Protein Protein Protein Protein RNA 
 I + - - - - - - - - + 
 II + - - - - + + + + + 
 III + + + + + + + + + + 
 
B cells display all three latency types. Generally, post-infection, EBV 
progresses from latency III to II to I. After entering a resting B cell, EBV is in 
latency III, which transforms the cell into a proliferating blast. Subsequently, the 
virus halts expression of several latent genes and enters latency II, resulting in 
the cell differentiating into a memory B cell. Ultimately, EBV enters latency I, 
expressing only EBNA1, which allows for EBV genome replication and 
partitioning upon cell division (23). Some B cell lines remain at latency III, such 
as lymphoblastiod cell lines (LCL) and the Raji cell line. In epithelial cells, EBV is 
only maintained in latency II. Latent infection of B cells may be necessary for viral 
persistence, replication and release of virions in saliva (24).  
Viral Genes and Functions 
EBNA1 
EBNA1 is perhaps the most important latent protein. EBNA1 is expressed 
in all types of latent EBV infection, and is found in all EBV-associated cancers. 
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EBNA1 exists in the cell as a dimer (25). EBNA1 has a glycine-alanine repeat 
sequence, which separates the protein into amino- and carboxy-terminal 
domains. The repeat sequence stabilizes the protein by preventing proteasome 
degradation as well as impairing antigen processing and MHC class I antigen 
presentation (26-28). This results in the inhibition of the CD8 cytotoxic T cell 
response against EBV-positive cells (29, 30). EBNA1 is the only protein 
expressed during latency type I (31). EBNA1 is involved in gene regulation, viral 
episome replication and partitioning among daughter cells after cell division (32). 
This occurs through EBNA1 binding to the origin of viral replication (oriP) (33). 
EBNA1 also binds to the host cell chromosome (22). These two interactions 
allow EBNA1 to mediate the aforementioned replication and partitioning of EBV 
genomes.  
EBNA2 
EBNA2 is the one of several EBV transactivator proteins. EBNA2 helps 
regulate latent viral transcription and therefore contributes to the transforming 
capability of EBV (34, 35). EBNA2 also has a role as an adapter protein, binding 
to DNA-binding proteins CBF1, also known as JK recombination signal protein 
(RBP-JK), PU.1 as well as some components of RNA polymerase II (34, 36). 
EBNA2 has a co-activator, EBNA-LP, which helps EBNA2 activate the LMP1 
promoter and LMP1/LMP2B transcriptional regulatory element (37). 
EBNA3 family  
The EBNA3 family includes EBNA3A, EBNA3B and EBNA3C. 
Investigations have found that EBNA3C is involved in the regulation of the cell 
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cycle (38). EBNA3A is also required in regulating cell cycle, and it was found that 
very specific levels of EBNA3A were necessary for LCL maintenance (39). 
Conversely, EBNA3B appears to restrain the oncogenic capacity of EBV, similar 
to a tumor suppressor (40). This combination of oncoproteins and tumor 
suppressor appears to be hitherto unique to EBV. 
EBNA-LP 
EBNA-LP is a phosphoprotein, which localizes predominately in the nucleus (41, 
42). EBNA-LP is an EBNA2 coactivator and is important for B-cell 
immortalization. In this role, EBNA-LP aids EBNA2 in its activation of the LMP1 
promoter and the LMP1/LMP2B transcriptional regulatory element (37). 
LMP1 
LMP1 is a membrane protein with six transmembrane spans that is essential for 
EBV-mediated growth transformation (43). LMP1 regulates its own expression as 
well as that of several host cell genes (44). LMP1 possesses the most potent 
transforming activity of the EBV latent proteins, and its expression is associated 
with many of the characteristics of activation of primary B cells and EBV 
infections (45). LMP1 is a homologue of tumor necrosis factor (TNF) and can 
mediate signaling in the nuclear factor-kB (NFkB) pathway, in place of CD40 
receptor signaling (44, 46).   
LMP2 
LMP2 includes LMP2A and LMP2B. LMP2A and LMP2B act to inhibit 
tyrosine kinase signaling. LMP2A is a transmembrane protein that inhibits normal 
B-cell signal transduction by mimicking an activated BCR. The N-terminus of 
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LMP2A associates with Src protein tyrosine kinases and spleen tyrosine kinase 
(Syk), both of which are involved in BCR signaling (47). LMP2B may inhibit such 
signaling.  
EBER (ncRNAs) 
Epstein-Barr virus-encoded small RNAs (EBERs) are small non-coding 
RNAs (ncRNAs) found in the nucleus of cells infected with EBV. EBERs are the 
most abundant RNA found in EBV-infected cells, and interact with host proteins 
to form ribonucleoprotein complexes (48). An exact role for EBERs is not yet 
known, but they may be involved in cell transformation and oncogenesis.  
Reactivation 
          Once latently infected, cells harboring EBV can switch to a lytic replication 
phase. Lytic replication includes transcription of a host of viral genes, which are 
categorized as immediate-early, early and late. This can be achieved in the 
laboratory with chemical or antibody-based agents, but the process by which this 
occurs in-vivo is not well understood. In-vitro, stimulation of the B cell receptor by 
anti-Ig cross-linking and a variety of chemical stimuli, such as sodium butyrate, 
phorbol esters, proteasome inhibitors and calcium ionophores can induce EBV to 
replicate lytically (49-53). Since anti-Ig reactivates cells in-vitro, in-vivo 
reactivation may take place in B cells when antibodies against an antigen present 
on the cell surface bind the infected cell. 
ZTA 
ZTA, also known as BZLF1, Zebra and Z, is an immediate-early viral gene 
of EBV.  The Z promoter, Zp, can be bound by a multitude of transcription 
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factors, and such binding facilitates Zta transcription. Similar to many 
transcription factors, ZTA has a leucine zipper domain, and exists as a 
homodimer (54, 55). The expression of ZTA is sufficient to turn on lytic 
replication, resulting in the production of infectious virions.  ZTA binds to oriLyt 
(lytic origin of replication) on the EBV genome, the BALF2 promoter and interacts 
with a number of replication proteins (56, 57). ZTA is widely used as an indicator 
of lytic replication in viral assays. ZTA can bind to Zta response elements 
(ZREs), such as those contained within the BRLF1 gene and the origin of 
replication (oriLyt) (58). 
RTA 
RTA is the product of the BRLF1 gene and functions as a transcriptional 
activator in both B and epithelial cells (59). Rta contains ZREs, sequences to 
which ZTA can bind to enhance transcription (58).  Rta expression has also been 
shown to reactivation in epithelial cells, and more recently in B cells. RTA-
induced latent disruption and subsequent lytic replication appears to be less 
potent than ZTA-induced lytic activation. Additionally, transfection of RTA into 
HH514-16 cells leads to ZTA synthesis and viral DNA replication (21).  
Transformation of B cells 
EBV has the capability of transforming B cells to divide indefinitely. To do 
so, B cells, separated from PBMCs are infected with EBV and maintained in 
culture. LMP1 seems to be the main driver of transformation, while EBNA2 and 
EBNA3C also play a role (34, 35, 38, 39, 45, 60).  
EBV types 
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Broadly, EBV has two subtypes – type I and type II. The main difference is 
in the EBNA2 and EBNA3 genes (61). This manifests itself in different 
transforming capabilities between the two subtypes of EBV. While type I is 
dominant around much of the world, in Africa, types I and II exist in equally 
distributed amounts. Restriction enzyme digestion of the viral genome enables 
distinction between the two types. Differential gene regulation between type I and 
type II EBV have been shown to account for the weaker B cell transformational 
capacity of type II EBV versus type I (62). 
Role in disease 
Infectious mononucleosis, Burkitt lymphoma, Hodgkin lymphoma, 
nasopharyngeal carcinoma, and other diseases have been linked to EBV (2-4). 
While most individuals will maintain EBV with no symptoms throughout their 
lifetime, immunocompromised patients are at an increased risk for EBV-related 
malignancies (6). 
B cells 
The B cell receptor and EBV activation 
The B cell receptor is composed of two parts: an immunoglobulin molecule 
including IgD, IgM, IgA, IgG or IgE and the signal transduction molecule CD79. 
Upon being bound by an anti-Ig molecule, the BCR signaling pathway is 
activated and results in a downstream phosphorylation cascade involving 
proteins such as LYN, SYK, PI3Kδ, PLC-γ, AKT, BTK and ERK (63, 64). This 
activation results in a calcium flux that can disrupt latently replicating EBV in 
certain cell lines (65, 66). 
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There are several drugs used to treat hematologic malignancies that block 
signaling kinases in the BCR pathway. Idelaliaib blocks PI3Kδ, ibrutinib blocks 
BTK and dasatinib blocks BTK and LYN as an off-target effect (it is used clinically 
to inhibit ABL kinase) (67-69). There may be cross-talk within this pathway, 
resulting in idelalisib blocking phosphorylation of BTK and ibrutinib blocking 
phosphorylation of PI3Kδ (70). 
B cell malignancies and EBV 
 There are a number of B cell cancers where EBV is involved. These 
include Burkitt lymphoma (BL), post-transplant lymphoproliferative disorder 
(PTLD), AIDS lymphoma and immunodeficiency lymphoma. 
Burkitt lymphoma 
 BL is a B lymphocyte malignancy originating in the jaw. BL presents most 
frequently in children in parts of the world where malaria is endemic. It is 
hypothesized that malaria infection weakens the hosts immune system, aiding 
EBV infection in taking hold and persisting, allowing it time to transform cells and 
result in cancer. The pathogenesis of AIDS-associated BL appears to differ from 
that of classic BL (71). 
Post-transplant lymphoproliferative disorder 
 PTLD is a malignant proliferation of B-lymphocytes, which carry EBV 
under latent replication. PTLD arises in immunosuppressed patients who have 
recently undergone transplant and are under a regimen of immunosuppressives, 
such as cyclosporine and tacrolimus which block T cell function. Blockade of T 
cell function and resultant loss of immunosurveillance is thought to allow EBV to 
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transform cells unchecked. Rapamycin, another immunosuppressive, leads to an 
increase in T cell function in certain cases (72).  
AIDS lymphoma 
 AIDS lymphoma describes lymphomas present in patients with AIDS. 
Generally, a pool of AIDS patients has an increased frequency of lymphomas 
than the general population. This observation is most likely due to a lack of 
immunosurveillance, parallel to PTLD.  
Immunodeficiency lymphoma 
 Lymphomas can also occur in patients with primary immunodeficiency. 
Such a case might occur in patients with Ataxia Telangiectasia and Wiskott-
Aldrich syndrome (73). Rather than being immunocompromised by 
immunosuppressive drugs or have an acquired immunodeficiency such as those 
affected by AIDS, or more mildly, malaria as in BL, these patients have rare, 












EBV establishes viral latency in B cells. Activation of the BCR pathway 
activates EBV in cell lines. This work demonstrates that drugs that inhibit kinases 
in the BCR signaling pathway inhibit activation of EBV, but do not inhibit several 
other lytic activation pathways. Immunosuppressant drugs cyclosporine and 
tacrolimus but not rapamycin also inhibit BCR-mediated EBV activation. 
Additionally, we show that BCR-activation of lytic infection occurs in freshly 




Chapter 1: Characterization of kinase inhibitors on EBV-positive cell lines 
SUMMARY 
Epstein-Barr virus is a human gammaherpes virus that primarily infects B 
cells. In an immunocompromised host with such an infection a variety of B cell 
malignancies have been observed. Several recently FDA-approved kinase 
inhibitors affect the BCR pathway, and it is possible to disrupt EBV latency by 
stimulation of this pathway. Thus we reasoned that the use of kinase inhibitors 
blocking the BCR pathway might have an impact on BCR-mediated EBV 
reactivation. We found that ibrutinib, which inhibits BTK, idelalisib, which inhibitits 
PI3Kδ, and dasatinib, which is used to target ABL kinase, but also inhibits LYN 
all inhibit BCR-mediated EBV reactivation at clinically relevant doses. We also 
found that siRNA knockdown of BTK, PI3Kδ and LYN resulted in a decrease in 
lytic induction by BCR pathway stimulation, confirming this pathway as being 
involved in such activation. Further confirmation of this was achieved by the 
observation of the inability of ibrutinib, idelalisib and dasatinib being unable to 
block induction of EBV lytic production by other lytic stimuli such as ionomycin, 
sodium butyrate and phorbol esters. Finally, we were able to show that in freshly 








Epstein–Barr virus (EBV) is a ubiquitous human gammaherpesvirus 
infection that is maintained in a fraction of resting memory B cells following 
primary infection (74-76). The elimination of B cells from blood following 
treatment with a B cell-targeting monoclonal antibody commonly results in an 
inability to detect EBV DNA in PBMCs (77). The reservoir of EBV in B cells 
appears to be necessary to maintain the virus as evidenced by the observation 
that chronic infection is not established in patients with Bruton 
agammaglobulinemia who lack B cells (76).  While the virus resides mainly in B 
cells, the character of the B cells in which the virus is harbored affects viral gene 
epression. In vitro, EBV infection of B cells results in immortalized LCLs 
expressing eight or more latency antigens whereas in vivo, in healthy 
seropositive adults the B cells that harbor viral genomes demonstrate very 
restricted viral gene expression. The germinal center reaction that occurs in 
lymphoid tissue is hypothesized to play a key role in down modulating viral gene 
expression (74). In some B cell tumor lines, BCR signaling is a potent activator of 
EBV lytic gene expression (78).  EBV gene expression, particularly expression of 
LMP2A and LMP2B influence the BCR signaling pathway (79). Thus B cells 
harbor EBV and B cell biology is important to the viral life cycle. 
Several pharmacologic agents that target B cell signaling pathways have 
come into clinical use. These include agents used because they target BCR 
signaling pathways such as ibrutinib, which inhibits BTK, and idelalisib which 
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inhibits PI3Kδ; and other agents with off-target effects on BCR signaling such as 
dasatinib, which targets Bcr-Abl kinase but also has effects on LYN.  
In this work, we show that some BCR signaling inhibitors profoundly inhibit 
BCR-driven activation of lytic infection in B cell tumor lines that harbor EBV. 
Finally, we show for the first time that BCR signaling is an activator of EBV lytic 
infection in naturally infected patient B cells and that ibrutinib and idelalisib block 


















Materials and Methods 
Reagents and Antibodies. Antibodies against phospho-AKT (Ser473) 
(Cat# 9272S), Akt, phospho-BTK (Tyr223) (Cat# 5082P), phospho-ERK 
(Thr202/Tyr204) (Cat# 9101S), and ERK (Cat# 4695S) were obtained from Cell 
Signaling Technologies. Antibodies against BTK were obtained from R&D 
Systems (Cat# MAB5807). Antibodies against phosopho-PI3Kδ (Tyr485) (Cat# 
sc-130211), PI3Kδ (Cat# sc-7176) and EBV ZTA (Cat# sc-53904) were obtained 
from Santa Cruz Biotechnology and against β-actin (Cat# A5441) from Sigma-
Aldrich. Anti-IgG and anti-IgM were purchased from Sigma-Aldrich (I5260 and 
I0759, respectively). In all experiments where used, anti-IgG and anti-IgM were 
used at 10 μg/mL. Secondary anti-mouse and anti-rabbit antibodies were 
purchased from Jackson Immunoresearch. Ibrutinib was purchased from 
ApexBio. Idelalisib and dasatinib were obtained from MedKoo. Ionomycin was 
purchased from Sigma-Aldrich.  
Cell Lines and Culture. An engineered Akata cell line derivative (BX1 
Akata) that carries a recombinant EBV that constitutively expresses a green 
fluorescent protein (GFP) was a gift from L. Hutt-Fletcher (80). BX1 Akata cells 
were cultured in RPMI 1640 media (Mediatech) with 10% FBS (Mediatech), 100 
units/mL penicillin, 100 μg/mL streptomycin (Life Technologies), 100 mM L-
glutamine (Life Technologies), and 500 μg/mL G418 (Life Technologies). 
Fluorescence Microscopy. 1.5x105 cells were taken from culture and 
washed with PBS. Cells were then spun onto microscope slides using a Cytospin 
centrifuge.  Cells were fixed and permeabilized with ice-cold methanol for 15 
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minutes and blocked in 5% BSA in PBS for 30 minutes at room temperature. ZTA 
antibodies (Santa Cruz) were diluted 1:50 in 5% BSA in PBS and applied to the 
cells for 1 hour at room temperature. The attached cells were then washed 3 
times for ten minutes each with 5% BSA, 0.1% Tween-20 in PBS. Cy3 goat anti-
mouse antibodies (Jackson Immunoresearch) were diluted 1:50 in 5% BSA in 
PBS and incubated with to the cells for 1h at room temperature in the dark. The 
slides were then washed 3 times for ten minutes each with 5% BSA, 0.1% 
Tween-20 in PBS. The cells were stained with Vectashield mounting media with 
DAPI (Vector Laboratories). For GFP, BX-1 Akata cells were cultured as above 
and treated as indicated in the figures. A ZOE Fluorescent Cell Imager  (Bio-Rad) 
was used to image the fixed cells for Cy3 and live cells expressing GFP. 
Quantitative PCR. DNA was isolated from cells with the QIAamp DNA 
isolation kit from Qiagen. Quantitative PCR assay of the Bam W repeat region of 
the EBV genome was performed for measuring viral load. A BamW probe 
(Integrated DNA Technologies) (5′ (FAM) 
CACACACTACACACACCCACCCGTCTC (BH1) 3′) was used in conjunction with 
SsoAdvance Supermix (Bio-Rad). BamW primers were obtained from Integrated 
DNA Technologies (fwd 5′ CCCAACACTCCACCACACC 3’ and rev 5′ 
TCTTAGGAGCTGTCCGAGGG 3′). Copy number was determined by comparing 
to a serial dilution of the Namalwa cell line.  The concentration of primers was 
500 nM. The probe concentration was 200 nM. 2 μL DNA at 50 ng/mL was used 
per reaction. Reaction size was 20 μL. The reaction was set at 95°C for 2 
minutes for 1 cycle and then 95°C for 5 seconds and 60°C for 10 seconds for a 
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total of 40 cycles on a CFX96 real time thermocycler from BioRad. For viral load 
quantification by qPCR, cells were treated with ibrutinib, idelalisib or dasatinib for 
1h prior to treatment with anti-IgG, and DNA was isolated after 48h. For Zta 
mRNA quantification, cells were treated as above and RNA was isolated after 
24h (RNEasy kit from Qiagen). cDNA was then made from the RNA using the 
iScript reverse synthase kit from BioRad. cDNA volume corresponding to 25 ng 
total RNA was amplified using the SsoFast Evagreen kit from BioRad on a 
CFX96 real time thermocycler from BioRad. The cDNA was amplified using a 
PCR program of 95°C for 30 seconds once and then 95°C for 5 seconds, and 
60°C for 5 seconds for 40 cycles. Primers used for Zta were fwd 
5’ACATCTGCTTCAACAGGAGG5 3’ and rev 5’AGCAGACATTGGTGTTCCAC 
3’. 
Immunoblots. For phospho-protein immunoblots, cells were serum-starved 
for three hours and pre-treated with ibrutinib, idelalisib or dasatinib for 1h before 
treatment by anti-IgG. Protein was isolated ten minutes after treatment by anti-
IgG. For ZTA blots, cells were treated with ibrutinib, idelalisib or dasatinib for 1 
hour prior to anti-IgG treatment and protein was extracted 24h after anti-IgG 
treatment. To prepare protein extracts, 1.5 X 107 cells were pelleted by 
centrifugation and washed in PBS. The pellet was resuspended in a 10 mM 
HEPES, pH 7.9, 10 mM KCl, 100 μM EDTA and 1X protease/phosphatase 
inhibitor cocktail (Cell Signaling Technologies) buffer and incubated on ice for 15 
min. NP-40 was added to a final concentration of 0.6% and the cells were lysed 
by brief vortexing. The cytosolic supernatant was separated from the nuclear 
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pellet by centrifugation at 10,000 rpm for 30s at 4°C. The nuclear pellet was 
resuspended in a 20 mM HEPES, pH 7.9, 400 mM NaCl, 1 mM EDTA buffer with 
1X protease/phosphatase inhibitor cocktail (Cell Signaling Technologies) 
followed by rotation for 15 minutes at 4°C. The nuclear supernatant was isolated 
by centrifugation at 13,000 rpm for 5 minutes at 4°C. Equal amounts of protein 
per sample were separated by SDS-PAGE and subsequently transferred to 
nitrocellulose membranes. After probing with primary antibodies, horseradish 
peroxidase-conjugated antibodies (GE) were applied against the primary 
antibodies. The immunoblots were imaged using Amersham ECL-Prime 
chemiluminescent reagent (GE Health). The film used was HyBlot CL 
autoradiography film (Denville Scientific). 
Statistical Analysis. IC50 values were calculated using Y=Ymin + (Ymax-
Ymin)/(1+10^((X-LogIC50))) in GraphPad Prism. 
Patient specimens.  With written informed consent and approval of the 
Johns Hopkins Hospital Investigational Review Board, blood was collected from 
two older adult patients with night sweats, fevers and elevated EBV copy number 
in PBMC.  Both had diffuse small lymphadenopathy (<2cm) and biopsies that 
showed atypical follicular hyperplasia with no evidence of clonality by 
immunohistochemistry or flow cytometry. Both patients were ultimately treated 
with rituximab and had only transient clinical responses. 
MACS isolation of patient B-cells. PBMCs were isolated from whole blood 
using the Ficoll gradient method. B cell subsets were isolated by depletion of 
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magnetically labeled non-B cells from patient PBMCs (B Cell Isolation Kit II, 
Miltenyi Biotec). 
siRNA knockdown. SMARTpool siRNA against BTK (M-003107-01-0005), 
LYN (L-003153-00-0005) and PIK3CD (L-006775-00-0005) were purchased from 
Dharmacon and nucleofected into BX1-Akata cells at 30 nM (BTK and LYN) and 
300 nM (PIK3CD). Nucleofection was carried out using a Nucleofector II device 
from Amaxa using Amaxa Cell Line Nucleofector Kit R according to the 
manufacturer’s specifications. Forty-eight hours after the initial nucleofection, the 
nucleofection was repeated on the same cells. 24 hours after the second 
nucleofection, the cells were treated with 10 μg/mL anti-IgG. Images were taken 















Previous investigators demonstrated that anti-Ig induces lytic EBV 
replication in the Akata Burkitt cell line (81).  We studied lytic gene expression 
and GFP expression in the BX1-Akata cell line, where GFP served as an 
indicator of lytic replication of EBV (Fig. 1-1 and 1-2). Induction with anti-Ig led to 
increased viral lytic RNA, protein, viral DNA, and increased GFP expression. 
Thus in the BX1-Akata cell line, GFP expression parallels other indications of 
EBV lytic gene expression.  We investigated whether or not BCR kinase 
inhibitors would block BCR-mediated EBV reactivation by treating with kinase 
inhibitors known to block BCR signaling: ibrutinib, idelalisib or dasatinib.  Each of 
these agents also decreased basal levels of Zta RNA and protein, likely reflecting 
inhibition of basal BCR signaling, and in combination with anti-Ig, blocked the 
induction of Zta RNA, ZTA protein, GFP fluorescence, and EBV DNA replication.   
To determine the potency of these drugs in blocking of BCR-mediated 
EBV activation, we performed dose-response experiments on BX1-Akata cells. 
We calculated the IC50 for inhibition of GFP expression (Fig. 1-3). These results 
parallel values reported in the literature for inhibition of BTK, PI3Kδ and LYN 
enzymatic activities (82-84). As shown in Fig. 1-4, these agents block anti-Ig 
induced phosphorylation of downstream B-cell receptor signaling proteins. Thus 
the pharmacodynamics of inhibition of EBV lytic induction paralleled the inhibition 
of the expected target pathway, i.e. ibrutinib, idelalisib and dasatinib all inhibited 
phosphorylation of AKT, ERK and PI3K. Note that clinically dasatinib is used to 
inhibit ABL kinase and inhibition of LYN is an off-target effect (84). To validate 
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the drugs specificity on their target genes, we undertook siRNA knockdown 
experiments against BTK, LYN and PI3K (Fig. 1-5). In each siRNA experiment, 
anti-IgG mediated increased GFP and Zta expression was blocked relative to 
control samples. 
To further explore the effects ibrutinib and idelalisib on EBV activation, we 
studied the effects of other EBV lytic inducers: ionomycin, TPA and NaB (Fig. 1-
6, 1-7 and 1-8). No inhibition of lytic activation was apparent. At lower doses of 
TPA and NaB, ibrutinib and idelalisib had no effect on lytic activation (data not 
shown). Thus inhibition of lytic induction is not a general phenomenon but seems 
to be specific to BCR-activated lytic induction. 
Although many investigators have documented the effects of BCR-
signaling on activation of EBV in a variety of cell lines (49, 78, 85), to the best of 
our knowledge these effects have never been documented directly in B cells from 
patients. For this investigation, we obtained PBMCs from two patients with high 
EBV copy number without malignancy. We isolated B-cells and treated with anti-
IgM in combination with ibrutinib or idelalisib (Fig. 1-9). We found that BCR 
stimulation activated EBV lytic replication as shown by increased viral DNA but 
that this effect was blocked by ibrutinib and idelalisib. Thus BCR signaling can 
activate EBV replication in non-malignant cells and pharmacologic agents that 









Figure 1-1. Ibrutinib, idelalisib and dasatinib block BCR-mediated EBV 
activation. BX1-Akata cells were treated with 1 μM ibrutinib, idelalisib or 
dasatinib for 1 hour, followed by induction with anti-IgG. A. qRT-PCR amplifying 
Zta cDNA 24 hours after treatment with anti-IgG normalized to GAPDH. B. 
Immunoblot showing ZTA 24 hours after treatment with anti-IgG. C.GFP-positive 
cells were quantified and compared with an untreated sample 24 hours after 
treatment. D. qPCR amplifying the BamW region of the EBV genome 48 hours 




Figure 1-2. Ibrutinib, idelalisib and dasatinib block BCR-mediated EBV 
activation. (Top panel) Immunofluorescence showing ZTA 24 hours after 
treatment with anti-IgG. (lower panel) fluorescent cells expressing GFP 24 hours 























Figure 1-3. Ibrutinib, idelalisib and dasatinib inhibit BCR-mediated 
EBV activation in a dose-dependent manner. GFP-positive cells were 
quantified and plotted against drug concentration 24 hours after anti-IgG 









Figure 1-4. Ibrutinib, idelalisib and dasatinib block B cell receptor 
pathway component phosphorylation. Cells were treated with 1 or 0.1 μM 
ibrutinib, idelalisib or dasatinib for 1 hour followed by induction with anti-IgG. 
Protein was isolated 10 minutes after anti-IgG treatment and analyzed by 









Figure 1-5. siRNA knockdown of drug targets results in decreased 
ability of B cell receptor pathway stimulation to induce lytic replication of 
Epstein-Barr virus. BX1-Akata cells were nucleofected with siRNA targeting the 
indicated transcripts followed by treatment with anti-IgG. qRT-PCR amplifying Zta 
cDNA 24 hours after treatment with anti-IgG. Zta levels were normalized to 








Figure 1-6. - BCR pathway kinase inhibitors in combination with other 
inducers. BX1-Akata cells were pretreated with the indicated kinase inhibitors for 
30 minutes and then treated with the indicated lytic inducers. Cells were imaged 
for GFP 24 hours after treatment with inducers.  Cells were treated with 1 μM 









Figure 1-7. Kinase inhibitors with other lytic gene inducers. BX1-Akata cells 
were pretreated with the indicated kinase inhibitors for 30 minutes and then 
treated with the indicated lytic inducers. Cells were imaged for GFP 24 hours 
after treatment with inducers. GFP-positive cells were quantified and compared 
to an untreated sample. Cells were treated with 1 μM ionomycin, 20 ng/mL TPA 














Figure 1-8. Ibrutinib and idelalisib do not block ionomycin-induced EBV. 
Immunofluorescence staining showing ZTA. BX1-Akata cells were pre-treated 
with the indicated kinase inhibitors and then treated with ionomycin after 1 hour. 

















BCR-mediated EBV activation in naturally infected EBV-positive B cells. 
EBV reactivation is inhibited by ibrutinib and idelalisib.  Peripheral blood 
mononuclear cells were obtained from two patients with high EBV copy number, 
but no malignancy. B cells were negatively selected using magnetic-activated cell 
sorting. Treatment with anti-IgM led to increased EBV genome amplification at 48 
hours. Pretreatment with 1μM ibrutinib or idelalisib 1 hour before anti-IgM 




This work demonstrates that drugs targeting the BCR pathway block BCR-
mediated EBV activation in EBV-positive Burkitt lymphoma cell lines. We were 
also able to show this effect in naturally infected B cells. Thus this phenomenon 
may be applicable in vivo as well. 
Ibrutinib, idelalisib and dasatinib are used in the treatment of various 
chronic B cell cancers (86, 87). The BCR effects of dasatinib are off-target, and 
while this drug is used to inhibit BCR-ABL, the off-target effect is potent enough 
to enable BCR pathway inhibition. These agents are typically administered until 
there is tumor progression, and patients may be treated with these compounds 
for years.  
It is possible that the BTK and PI3Kδ inhibitors will have an effect on the 
long-term EBV reservoir and EBV. If maintenance of that EBV reservoir requires 
periodic infection of previously uninfected cells, then inhibiting EBV lytic 
production might alter the ability to maintain that EBV reservoir. Inhibiting lytic 
replication and subsequent infection of new cells might result in fewer EBV-
positive cells and reduced EBV malignancy. Alternatively, if periodic EBV 
activation results in the death of virus harboring cells that might evolve to 
cancerous cells, then blocking lytic activation might increase EBV malignancy.  
The results seen here suggest that stimulation of the BCR pathway leads 
to EBV activation in freshly isolated peripheral blood B cells in vitro. Furthermore, 
drugs that block important kinases of the BCR pathway blocked EBV activation in 
vitro and in freshly isolated B cells. As these drugs are more commonly used and 
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typically are treated over long periods of time, further studies of their effects on 
EBV-associated phenomena are worth being undertaken. Inhibitors of BTK, such 
as ibrutinib, are widely used in treating chronic lymphocytic leukemia. It has been 
suggested that EBV copy number may have prognostic significance, and EBV-
related complications are well recognized. Thus the impact of these agents in 



















Chapter 2: Characterization of immunosuppressants on B cell receptor-
mediated activation of Epstein-Barr virus 
Summary 
The immunosuppressive drug rapamycin blocks a component of the B cell 
receptor pathway, mTORC1. Therefore, one might expect rapamycin to block 
BCR-mediated lytic induction of EBV. While the immunosuppressive drugs 
cyclosporine and tacrolimus inhibit BCR-driven activation of lytic infection, 
rapamycin, also an immunosuppressive drug, does not. Rapamycin also binds to 
FKBP12. Non-immunosuppressive analogs of tacrolimus, which bind FKBP12 
but not calcineurin, did not block anti-Ig-mediated EBV activation. Torin2, an 
mTORC1 and mTORC2 inhibitor blocks anti-Ig-mediated activation of EBV, 
suggesting that mTORC2 contributes to the signaling cascade from the B cell 
receptor that results in the activation of EBV. Finally, the difference between the 
effects of calcineurin inhibitors and rapamycin on EBV reactivation following BCR 
pathway stimulation suggests the possibility that supplanting treatment by 
calcineurin inhibitors with rapamycin could result in a lower incidence of post-









Calcineurin inhibitors and rapamycin are both inhibitors of T cell function 
and are used in transplantation to prevent organ rejection in solid organ 
transplantation or graft versus host disease in hematopoietic cell transplantation. 
In some cases, EBV-driven B cell malignancies can arise as a result of loss of 
immunosurveillance of EBV-transformed cells. As was previously shown (53), 
calcineurin inhibitors block EBV activation following BCR stimulation. A recent 
study found that in renal transplant recipients who were EBV-seronegative prior 
to transplant, treatment with rapamycin and mycophenolate was associated with 
a lower risk of post-transplant lymphoproliferative disease than tacrolimus or 
mycophenolate (88).   
 In the previous chapter, modulators of the B cell receptor pathway 
resulted in the blocking of anti-Ig-mediated activation of EBV. The 
immunosuppressive rapamycin also blocks a component (albeit farther 
downstream) of the B cell receptor pathway, mTORC1. Rapamycin also binds to 
FKBP12, a binding domain it shares with tacrolimus. We therefore set out to 








Materials and Methods 
Reagents and Antibodies. Antibodies against phospho-AKT (Ser473) 
(Cat# 9271L), were obtained from Cell Signaling Technologies. Antibodies 
against EBV ZTA (Cat# sc-53904) were obtained from Santa Cruz Biotechnology 
and against β-actin (Cat# A5441) from Sigma-Aldrich. Anti-IgG was purchased 
from Sigma-Aldrich (I5260). Antibodies against phospho-S6K (Thr389) (Cat# 
56311) were purchased from Sigma-Aldrich. Antibodies against phospho mTOR 
(Ser2448) (Cat# 2971S) and mTOR (Cat# 2972S) were purchased from Cell 
Signaling Technologies. Rapamycin (Cat# 37094), Torin2 (Cat# SML1224) and 
tacrolimus (Cat# F4679) were purchased from Sigma-Aldrich. In all treatments, 
anti-IgG was used at 10 μg/mL. Secondary anti-mouse and anti-rabbit antibodies 
were purchased from Jackson Immunoresearch. Ibrutinib was purchased from 
ApexBio. Idelalisib and dasatinib were obtained from MedKoo. Ionomycin was 
purchased from Sigma-Aldrich. Non-immunosuppressive FK506 analogues were 
synthesized and characterized as described below.  
Cell Lines and Culture. An engineered Akata cell line derivative (BX1 
Akata) that carries a recombinant EBV that constitutively expresses a green 
fluorescent protein (GFP) was a gift from L. Hutt-Fletcher (80). BX1 Akata cells 
were cultured in RPMI 1640 media (Mediatech) with 10% FBS (Mediatech), 100 
units/mL penicillin, 100 μg/mL streptomycin (Life Technologies), 100 mM L-
glutamine (Life Technologies), and 500 μg/mL G418. Jurkat cells were cultured in 
RPMI 1640 media (Mediatech) with 10% FBS (Mediatech), 100 units/mL 
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penicillin, 100 μg/mL streptomycin (Life Technologies), and 100 mM L-glutamine 
(Life Technologies). 
Fluorescence Microscopy. 1.5x105 cells were taken from culture and 
washed with PBS. Cells were then spun onto microscope slides using a Cytospin 
centrifuge.  Cells were fixed and permeabilized with ice-cold methanol for 15 
minutes and blocked in 5% BSA in PBS for 30 minutes at room temperature. ZTA 
antibodies (Santa Cruz) were diluted 1:50 in 5% BSA in PBS and applied to the 
cells for 1 hour at room temperature. The attached cells were then washed 3 
times for ten minutes each with 5% BSA, 0.1% Tween-20 in PBS. Cy3 goat anti-
mouse antibodies (Jackson Immunoresearch) were diluted 1:50 in 5% BSA in 
PBS and applied to the cells for 1h at room temperature in the dark. The slides 
were then washed 3 times for ten minutes each with 5% BSA, 0.1% Tween-20 in 
PBS. The cells were stained with Vectashield mounting media with DAPI 
purchased from Vector Laboratories. For GFP, BX-1 Akata cells were cultured as 
above and treated as indicated in the figures. A ZOE Fluorescent Cell Imager  
(Bio-Rad) was used to image the fixed cells for Cy3 and live cells for GFP. 
Quantitative PCR. DNA was isolated from cells using the QIAamp DNA 
isolation kit from Qiagen. Quantitative PCR assay of the Bam W repeat region of 
the EBV genome was performed for measuring viral load. A BamW probe 
(Integrated DNA Technologies) (5′ (FAM) 
CACACACTACACACACCCACCCGTCTC (BH1) 3′) was used in conjunction with 
SsoAdvance Supermix (Bio-Rad). BamW primers were obtained from Integrated 
DNA Technologies (fwd 5′ CCCAACACTCCACCACACC 3’ and rev 5′ 
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TCTTAGGAGCTGTCCGAGGG 3′). Copy number was determined by comparing 
to a serial dilution of the Namalwa cell line.  The concentration of primers was 
500 nM. The probe concentration was 200 nM. 2 μL DNA at 50 ng/mL was used 
per reaction. Reaction size was 20 μL. The reaction was set at 95°C for 2 
minutes for 1 cycle and then 95°C for 5 seconds and 60°C for 10 seconds for a 
total of 40 cycles on a CFX96 real time thermocycler from BioRad. For viral load 
quantification by qPCR, cells were treated with ibrutinib, idelalisib or dasatinib for 
1h prior to treatment with anti-IgG, and DNA was isolated after 48h. For Zta 
mRNA quantification, cells were treated as above and RNA was isolated after 24 
hours (RNEasy kit from Qiagen). cDNA was then made from the RNA using the 
iScript reverse synthase kit from BioRad. cDNA volume corresponding to 25 ng 
total RNA was amplified using the SsoFast Evagreen kit from BioRad on a 
CFX96 real time thermocycler from BioRad. The cDNA was amplified using a 
PCR program of 95°C for 30 seconds once and then 95°C for 5 seconds, and 
6°C for 5 seconds for 40 cycles. Primers used for Zta were fwd 
5’ACATCTGCTTCAACAGGAGG5 3’ and rev 5’AGCAGACATTGGTGTTCCAC 
3’. 
Immunoblots. For phospho-protein immunoblots, cells were serum-starved 
for three hours and pre-treated with ibrutinib, idelalisib or dasatinib for 1h prior to 
treatment by anti-IgG. Protein was isolated ten minutes after treatment by anti-
IgG. For ZTA blots, cells were treated with ibrutinib, idelalisib or dasatinib for 1 
hour prior to anti-IgG treatment and protein was extracted 24h after anti-IgG 
treatment. To prepare protein extracts, 1.5 X 107 cells were pelleted by 
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centrifugation and washed in PBS. The pellet was resuspended in a 10 mM 
HEPES, pH 7.9, 10 mM KCl, 100 μM EDTA and 1X protease/phosphatase 
inhibitor cocktail (Cell Signaling Technologies) buffer and incubated on ice for 15 
min. NP-40 was added to a final concentration of 0.6% and the cells were lysed 
by brief vortexing. The cytosolic supernatant was separated from the nuclear 
pellet by centrifugation at 10,000 rpm for 30s at 4°C. The nuclear pellet was then 
resuspended in a 20 mM HEPES, pH 7.9, 400 mM NaCl, 1 mM EDTA buffer with 
1X protease/phosphatase inhibitor cocktail (Cell Signaling Technologies) 
followed by rotation for 15 minutes at 4°C. The nuclear supernatant was isolated 
by centrifugation at 13,000 rpm for 5 minutes at 4°C. Equal amounts of protein 
per sample were separated by SDS-PAGE and subsequently transferred to 
nitrocellulose membranes using an iBLOT transfer device (Life Technologies). 
After probing with primary antibodies, horseradish peroxidase-conjugated 
antibodies (GE) were applied against the primary antibodies. The immunoblots 
were imaged using Amersham ECL-Prime chemiluminescent reagent (GE 
Health). The film used was HyBlot CL autoradiography film (Denville Scientific). 
Luciferase reporter assay.  NFAT luciferase reporter assay was performed 
as described previously (89).  Briefly, Jurkat T cells transfected with an NFAT 
reporter construct were seeded into 96 well plates at a density of 
5x104/180μL/well. Drugs were serially diluted in DMSO as 1000X stocks, which 
were subsequently diluted to 20X in serum-free RPMI 1640 media before 
addition to the 96 well plates. After 30 minutes of drug incubation, 40 nM of 
phorbol myristate acetate (PMA) and 1 μM of ionomycin were added to stimulate 
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cells. After a 6-hour incubation, plates were centrifuged and the supernatant was 
removed. Cells were immediately lysed in situ by adding 100 μL/well lysis buffer 
and kept at room temperature for 30 minutes. The luciferase activity was 
determined with sequential injection of luciferin solution into each well followed 
by photon emission detection (Glomax reader, Promega).  
Synthesis and characterization of FK506 analogs.  
Compound C: To a mixture of 4-vinylbenzyl chloride (A, 0.4 g, 2.6 mmol), 
K2CO3 (1g, 7.2 mmol), KI (0.1g, 0.6 mmol) in anhydrous DMF (5 mL) under Ar 
was added 1-naphthol (B, 0.3g, 2 mmol). After stirring for 40h at RT, the reaction 
was quenched with 100 ml H2O. The mixture was extracted with DCM, washed 
with brine, dried and concentrated. The resulting residue was purified by silica 
gel column using 10% ethyl acetate in hexane as an eluent to give compound C 
as a white solid. Yield: 62%. 1H-NMR (500 MHz, CDCl3) δ 8.36 – 8.32 (m, 1H), 
7.82-7.79 (m, 1H), 7.52 – 7.42 (m, 8H), 6.88 (d, J = 7.3 Hz, 1H), 6.75 (dd, J = 
17.6, 11.0 Hz, 1H), 5.78 (dd, J = 17.5, 0.8 Hz, 1H), 5.27 (dd, J=11.0, 0.7 Hz, 1H), 
5.24 (s, 2H). 
FKN4: To a solution of FK506 (D, 10 mg, 0.012 mmol) and compound C 
(15.6 mg, 0.187 mmol) in anhydrous DCE (3 mL), 10 mol% Hoveyda-Grubbs 2nd 
generation catalyst in anhydrous DCE (1mL) was added at rt (90, 91). The 
reaction was irradiated under microwave for 5 minutes at 140oC with shaking. 
The mixture was filtered and thoroughly washed with DCM (5×3ml). The filtrate 
was collected, concentrated, and resuspended in DMSO for LC-MS analysis and 
purification. Yield: 30%. 1H-NMR (500 MHz, CDCl3) δ 8.31 – 8.25 (m, 1H), 7.77 – 
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7.72 (m, 1H), 7.46 – 7.35 (m, 8H), 6.82 (d, J=7.3Hz, 1H), 6.36 (d, J=15.5Hz, 1H), 
6.13-6.01 (m, 1H), 5.27(s, 1H), 5.17 (s, 2H), 5.07-4.97 (m, 3H), 4.60-4.56 (m, 
1H), 4.37 (d, J=14Hz, 1H), 4.20 (s, 1H), 3.95-3.77 (m, 2H), 3.65-3.60 (m, 1H), 
3.55-3.47 (m, 1H), 3.37-3.29 (m, 13H), 2.99-2.90 (m, 2H), 2.79-2.70 (m, 1H), 
2.64-2.50 (m, 2H), 2.32-2.18 (m, 4H), 2.06-2.0(m, 2H), 1.78-1.65 (m, 5H), 1.65-
1.54 (m, 14H), 0.94-0.84 (m, 9H), 0.84-0.80 (m, 3H). Mass spectrometry: found 
m/z=1059.1. [M + Na]+, calculated 1036.3. 
FKAM: To a solution of FK506 (100 mg, 0.120 mmol) and 30 mol% 
Zhan1b ruthenium catalyst in 3 mL anhydrous DCE, 4-allylmorpholine (18.1 µL, 
0.132 mmol) was added. The mixture was stirred for 30 sec before microwave 
irradiation at 120°C for 20 mins. The crude product was then purified using flash 
chromatography (0-25% gradient MeOH in DCM), followed by preparative-TLC 
(9:1 DCM:MeOH). Yield: 25%. 1H-NMR (500 MHz, CDCl3) δ 5.51 (s, 2H), 5.33 (s, 
1H), 5.19 (s, 1H) 5.12-4.98 (m, 2H), 4.60-4.40 (m, 1H), 3.98-3.85 (m, 1H), 3.75-
3.65 (d, 5H), 3.61-3.56 (d, 1H), 3.42-3.32 (m, 8H), 3.3 (s, 2H), 3.05-2.89 (m, 3H), 
2.76-2.65 (m, 2H), 2.43 (s,5H), 2.35-2.25 (m, 2H), 2.20-2.12 (d, 2H), 2.10-1.93 
(dd, 4H), 1.89 (s, 1H), 1.79-1.71 (m, 2H), 1.70-1.55 (m, 7H), 1.51-1.41 (m, 2H), 
1.34-1.16 (m, 11H), 1.08-1.12 (d, 2H), 1.12-0.97 (d, 2H), 0.96-0.79(dt, 9H). High-






It has been previously reported that anti-Ig induction of the EBV lytic cycle 
in Akata cells can be blocked by the immunosuppressant drugs cyclosporin A 
and tacrolimus (53). As shown in Fig. 2-1a, we first confirmed the observation 
that cyclosporine A and tacrolimus block anti-IgG-induced EBV lytic activation. It 
appears that rapamycin weakly activates lytic infection (Fig. 2-2b). This may 
reflect activation of a feedback loop between mTORC1 and AKT. 
Previous investigations reported that rapamycin inhibited EBV lytic 
activation, albeit in different cell types and in conjunction with other lytic inducers 
(92). However, rapamycin, does not block anti-Ig-induced EBV activation (Fig. 2-
1c and 2-2c). The investigators who had reported inhibition of lytic EBV infection 
with rapamycin had not studied anti-Ig induced EBV activation but instead had 
studied NaB and TPA EBV activation. This led us to investigate differential 
effects of immunosuppressants on EBV lytic activation by various inducers. We 
pretreated cells with cyclosporine A, tacrolimus or rapamycin followed by 
treatment with anti-IgG, NaB, TPA or ionomycin. We confirmed the previous 
report that rapamycin blocked NaB and TPA-induced EBV lytic activation (Fig. 2-
1e) and found that cyclosporine A and tacrolimus did not (data not shown). In 
contrast, while cyclosporine A and tacrolimus block ionomycin-induced EBV lytic 
activation, rapamycin does not (Fig. 2-1d, 2-2d). These results suggest that 
cyclosporine A, tacrolimus and rapamycin, although all immunosuppressive 
agents, have very different effects on EBV activation. 
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Tacrolimus and rapamycin both form binary complexes with FKBP (93). 
The FKBP-tacrolimus complex binds to and inhibits the enzymatic activity of the 
protein phosphatase calcineurin, blocking calcium-dependent intracellular 
signaling, while the FKBP-rapamycin complex binds to the protein kinase mTOR. 
Tacrolimus and rapamycin share a nearly identical FKBP-binding domain (FKBD) 
but each possesses distinct effector domains responsible for interactions with 
calcineurin and mTOR, respectively. The failure of rapamycin to inhibit Ig-
induced lytic activation suggested that binding FKBP is not sufficient to block 
EBV lytic activation. To further verify this hypothesis, we synthesized two non-
immunosuppressive analogs of tacrolimus and investigated their effects on EBV 
lytic activation by anti-IgG (Fig. 2-3). The two analogues, FKAM and FKN4, share 
the same FKBP-binding domain, but have altered effector domains. Thus, new 
substitutions were added to the allyl group of FK506 to generate FKN4 and 
FKAM, respectively (Fig. 2-4). The presence of the newly added ‘bumps’ in the 
effector domain of FK506 is expected to prevent FKN4 and FKAM from binding 
to calcineurin without affecting their interactions with FKBP. The lack of inhibition 
of calcineurin was verified using an NFAT-luciferase reporter gene, which upon 
transfection into Jurkat T cells, can be stimulated by PMA and ionomycin.  While 
FK506 potently inhibited the NFAT-luciferase reporter, neither FKN4 nor FNAM 
had an appreciable effect on the reporter activity at the highest concentrations 
tested (Fig. 2-5). The interactions of FKN4 and FKAM with FKBP are 
demonstrated by their ability to compete with FK506 and block inhibition of 
NFAT-luciferase (Fig. 2-6). Next, we determined the effects of the non-
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immunosuppressive analogs on EBV lytic activation in response to anti-IgG 
stimulation. BX1-Akata cells were pre-treated with these analogs at varying 
doses for 1 hour and then induced with anti-IgG. EBV activation was assessed 
by GFP expression 24 hours post-treatment. Neither FKN4 nor FKAM affected 
GFP expression induced by anti-IgG, further supporting the notion that FKBP-
binding is not sufficient to block EBV lytic activation and inhibitory effects 
observed for cyclosporine A and tacrolimus were mediated through inhibition of 
calcineurin (Fig. 2-7). 
To further investigate the impact of blocking mTOR signaling on EBV lytic 
activation, we used the mTOR active site inhibitor torin2. While rapamycin 
inhibits mTOR complex1 (mTORC1), torin2 has been shown to block both 
mTORC1 and mTORC2 (94). BX1-Akata cells were pre-treated with either 
rapamycin or torin2 and induced with anti-IgG after 30 minutes. ZTA expression 
was assessed by immunofluorescence and immunoblot, while Zta RNA level was 
assessed by qRT-PCR 24 hours after the treatment (Fig. 2-8 and 2-9). 
Rapamycin did not block anti-IgG induced EBV lytic activation, but torin2 did. 
Treatment by anti-IgG increased phosphorylation of mTOR, AKT and S6K, a 
downstream target of mTOR kinase. We found that both rapamycin and torin2 
blocked phosphorylation of mTOR as well as its downstream target, S6K (Fig. 2-
10). However, profound inhibition of AKT phosphorylation was shown after 30 
minutes in torin2 treated cells, as it blocks both mTORC1 and mTORC2, which 
has a positive feedback loop with AKT. Rapamycin also blocked phosphorylation 
of AKT, but to a lesser degree. Torin2 treatment alone also resulted in a 
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decrease in ZTA expression, likely due to inhibition of basal BCR signaling (Fig. 
2-1). These results suggest that mTORC2 and likely AKT activity is crucial for 
























Figure 2-1. Rapamycin does not block anti-IgG induced lytic activation.  A. 
BX1-Akata cells were pre-treated with 1 μM CsA or 10 nM TAC for 1 hour, 
followed by treatment with anti-IgG. B. BX1-Akata cells were treated with various 
doses of rapamycin (R). C and D. BX1-Akata cells were pre-treated with 
rapamycin using varying doses for 1 hour and followed by induction with anti-IgG 
(C) or ionomycin (D). E. BX1-Akata cells were treated with rapamycin for 1 hour, 
followed by treatment with NaB or TPA. Cells were treated with 1 μM ionomycin, 
20 ng/mL TPA or 3 mM NaB unless otherwise indicated. 
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Figure 2-2. Rapamycin does not block BCR-mediated or calcium ionphore-
mediated lytic EBV. Fluorescence microscopy was used to determine the 
number of GFP-positive cells. GFP-positive cells were quantified and values 
were graphed as a function of the experimental control. A, B, C, and D are 
quantification of Figure 2-1 A, B, C and D, respectively. Cells were treated with 1 


























































































































































































































































































Figure 2-3. Synthesis of tacrolimus analogs. A. Synthetic scheme of FKN4. B. 





































Reagents and conditions:(a) K2CO3, KI, DMF, RT, 40h, A:B=1.3:1; (b) Hoveyda-Grubbs Catalyst 2nd, DCE, 140
oC, 5min, D:C=1:5;
A                    B                                                                     C







Figure 2-4.  
Structures of FK506, rapamycin and non-immunosuppressive FK506 
analogs FKN4 and FKAM. The newly added substitutions in FKN4 and FKAM 






































































Figure 2-5. Effects of FK506, FKN4 and FKAM on the activation of an 
NFAT-luciferase reporter gene stimulated with PMA and ionomycin in 
Jurkat T cells. After 30 minutes of drug incubation, 40 nM of phorbol myristate 
acetate (PMA) and 1 μM of ionomycin were added to stimulate cells. After a 6-
hour incubation, cells were lysed and kept at room temperature for 30 minutes, 







































Figure 2-6. FK506 analogs and rapamycin reverse FK506 effects in an NFAT 
luciferase reporter gene competition assay in stimulated Jurkat T cells.  
Effects of FK506, FKN4, FKAM and rapamycin on the activation of an NFAT-
luciferase reporter gene stimulated with PMA and ionomycin in Jurkat T cells. 
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Figure 2-7. Nonimmunosuppressive FK506 analogs do not block BCR-
mediated induction of EBV. BX1-Akata cells were pre-treated with tacrolimus 
and tacrolimus analogs FKAM and FKN4 using varying doses for 1 hour followed 
by induction with anti-IgG for 24 hours. A. Fluorescent cells were imaged for 
GFP. B. GFP-positive cells were counted and compared with an untreated 
sample.  










Figure 2-8. mTORC2 activity is crucial for B cell receptor (BCR)-mediated 
EBV lytic activation. BX1-Akata cells were pre-treated with rapamycin (R) or 
torin2 (T) for 30 minutes followed by induction with anti-IgG. A. Zta RNA level 
was measured by qRT-PCR 24 hours after either rapamycin or torin2 treatment 
and normalized to GAPDH. B. ZTA protein level was assessed by immunoblot 24 






Figure 2-9. Torin2, but not rapamycin, blocks lytic induction of EBV. BX-1 
Akata cells were pretreated with the mTORC1 inhibitor rapamycin and the 
mTORC1 and mTORC2 inhibitor torin2 for 30 minutes prior to treatment with 






















Figure 2-10. Torin2, but not rapamycin, blocks phosphorylation of mTOR 
and S6K. BX-1 Akata cells were pretreated with the mTORC1 inhibitor 
rapamycin and the mTORC1 and mTORC2 inhibitor torin2 for 30 minutes prior to 
treatment with anti-IgG. Phosphorylation of AKT, mTOR and S6K were assessed 













- + - + - + 
- - R R T T 
 56 
Discussion 
Immunosuppressive treatments have been shown to play a central role in 
pathogenesis of EBV-associated lymphoproliferative diseases (95). The onset of 
disease is believed to be due to the effects of immunosuppressives on T cell 
function and loss of immune system control of EBV-driven B-cell 
lymphoproliferation (96). More recently, rapamycin has replaced or been used in 
combination with calcineurin inhibitors for therapy in many transplantation 
regimens. Studies have suggested that while calcineurin inhibitors block T cell 
function, in some cases, rapamycin has the opposite effect (72).  
While calcineurin inhibitors and rapamycin are both used as 
immunosuppressants in transplant regimens and both block T cell function, they 
have opposite effects on BCR-mediated EBV activation. As previously reported 
(53) and confirmed here, tacrolimus and cyclosporine inhibit BCR-mediated EBV 
activation. Interestingly, we found that rapamycin did not block such activation. 
Therefore, in the setting of post-transplant lymphoproliferative disease, these 
drugs may have different outcomes. There is a possibility that EBV-driven 
malignancies, which arise under a treatment regimen of calcineurin inhibitors, 
may be less viable in the presence of rapamycin alone. 
 The differences in post-transplant lymphoproliferative disease between 
rapamycin and calcineurin inhibitors indicate that further work analyzing the role 
of BCR-mediated EBV activation may prove useful in uncovering causative 




The studies presented here demonstrate that pharmacologic agents 
targeting the BCR pathway block BCR-mediated activation of the EBV lytic cycle. 
Furthermore, with the investigation of unmanipulated, naturally infected B cells 
isolated from human host, we have presented evidence that BCR activation may 
be relevant in vivo as well. 
Since the early days of organ transplantation, pharmacologic agents have 
been recognized to play an important role in the pathogenesis of EBV-associated 
lymphoproliferative diseases (95). Immunosuppressive agents such as 
azathioprine, cyclosporine, tacrolimus, mycophenolate, anti-thymocyte globulin, 
OKT3 and others have been associated with an increased risk of post-transplant 
lymphoproliferative disease. The increased risk was generally attributed to drug 
effects on T cell function and resultant loss of control of EBV-driven B-cell 
lymphoproliferation (96). In more recent years, rapamycin has often replaced or 
supplemented calcineurin inhibitors in many transplantation regimens. Evidence 
has been presented that demonstrate the calcineurin inhibitors block T cell 
function, whereas in some special instances rapamycin enhances T cell function 
(72). For example, in a genetic immunodeficiency syndrome associated with 
activation of PI3Kδ, rapamycin has shown promise as a therapeutic because it 
enhances antiviral T cell function (97). Similarly, rapamycin may correct the 
antiviral deficiency associated with belatacept, a second-generation CTLA4-Ig 
derivative used in organ transplantation (72). 
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In this report, our focus is not on T cells but on B cells (98). With regard to 
B cells, it has previously been reported that cyclosporine and tarcrolimus 
increase the viability of spontaneous EBV-lymphoblastoid cell lines, possibly 
reflecting partial protection from Fas-mediated apoptosis and this phenomenon 
may also occur in vivo and play a role in the pathogenesis of post-transplant 
lymphoproliferative disorder (99). Conversely, antibody mediated B cell depletion 
has long been recognized as an effective intervention for EBV-associated post-
transplant lymphoproliferative disease (77, 100). The EBV latency reservoir is the 
resting B cell and depleting the B cell reservoir reduces both pools of infected 
cells and those that might become infected (101). 
Little is known of the regulation of viral activation in latently infected B cells 
in vivo, but certainly BCR signaling may play a role. BCR signaling has been 
used as a tool in the laboratory to activate lytic infection in certain cell lines in 
vitro for many years. In this work, we show that BCR signaling also activates lytic 
infection in freshly isolated, naturally infected B-lymphocytes from human host. 
Furthermore, we show that pharmacologic agents that inhibit BCR signaling also 
inhibit EBV lytic activation. 
These BCR inhibitors in aggregate are used in the treatment of chronic 
lymphocytic leukemia, mantle cell lymphoma, Waldenstrom macroglobulinemia, 
marginal zone lymphoma, follicular lymphoma and chronic myeloid leukemia (86, 
87). We note that the BCR effects of dasatinib on BCR signaling are off target 
and that the agent is used to inhibit BCR-ABL in the treatment of chronic 
myelocytic leukemia. All of these agents are orally administered and in contrast 
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to earlier generations of antineoplastic are typically prescribed until there is tumor 
progression, i.e. patients may be treated with these agents for months or years. 
None of these malignancies is typically associated with EBV, although high EBV 
copy number in blood has been reported in some patients with chronic 
lymphocytic leukemia (102, 103) and chronic lymphocytic leukemia may evolve 
into EBV-associated diffuse large B cell lymphoma or Hodgkin lymphoma (104, 
105). 
We suspect that the BTK and PI3Kδ inhibitors will impact the long-term 
EBV reservoir and EBV viremia. However, it is difficult to predict from first 
principles what these effects will be. Thus, if sustenance of that reservoir 
required intermittent infection of previously uninfected cells, then blocking EBV 
activation might interfere with the ability to maintain that reservoir. Preventing 
lytic replication and new rounds of infection might result in fewer EBV-infected 
cells and less EBV malignancy. Alternatively, if periodic lytic EBV activation 
results in the death of virus harboring cells that might evolve to malignant cells, 
then blocking lytic activation might increase EBV malignancy.  
Although calcineurin inhibitors and rapamycin are both inhibitors of T cell 
function and are both used in transplantation to suppress or prevent organ 
rejection in solid organ transplantation or graft versus host disease in allogeneic 
hematopoietic cell transplantation, these agents have markedly different effects 
from each other on BCR-mediated EBV activation in B cells. As was previously 
shown (53) and confirmed here, the calcineurin inhibitors block EBV activation 
following BCR stimulation, whereas such activation is not inhibited by rapamycin 
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in our experiments. Thus these agents may be expected to have very different 
effects with regard to post-transplant lymphoproliferative disease. A recent report 
indicated that in renal transplant recipients who were EBV-seronegative prior to 
transplant, treatment with rapamycin and mycophenolate was associated with a 
lower risk of post-transplant lymphoproliferative disease than tacrolimus and 
mycophenolate (88). Whether the difference in post-transplant 
lymphoproliferative disease reflects drug effects on T cells or B cells or both is 
not known. 
In conclusion, our investigations suggest that stimulation of the BCR 
pathway leads to EBV lytic induction in freshly isolated peripheral blood B cells in 
vitro. Furthermore, inhibitors of the BCR pathway block EBV activation in vitro 
and in freshly isolated B cells from human host. Finally, in contrast to calcineurin 
inhibitors, rapamycin does not inhibit BCR-driven EBV activation.  As these drugs 
are increasingly used widely and usually are used continuously for chronic 
disease over months or years, it seems that further investigation of their effects 
on EBV-associated phenomena are indicated. The BTK inhibitors are widely 
used in chronic lymphocytic leukemia. There is a suggestion that EBV copy 
number in blood may have prognostic significance, and EBV-related 
complications though rare are well recognized. Thus the impact of these agents 
in chronic lymphocytic leukemia would seem to be an appropriate focus of future 
research. Similarly, with differences in incidence of EBV-associated post-
transplant lymphoproliferative disease associated with regimens that include 
calcineurin inhibitors, further investigation of the possible role of BCR-mediated 
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EBV activation in the pathogenesis of post-transplant lymphoproliferative disease 
























We are interested in the possibility that by pharmacologically activating or 
inhibiting pathways in B cells, it will be possible to prevent or treat EBV-
associated B cell malignancies. There are several barriers to easily determining 
what effect activating or blocking B cell pathways in the context of EBV activation 
has on EBV-associated B cell malignancies.  
To start, it is not possible to predict the long-term effects of inhibiting B cell 
signaling. With regard to EBV, the inhibition of B cell signaling and thus baseline 
lytic activation might ultimately abolish the EBV reservoir if B cell signaling and 
resultant lytic infection is necessary for viral maintenance. This could manifest 
itself in a regression of EBV-associated malignancy. Conversely, if B cell 
pathway inhibitors block basal EBV activation and resultant cell death, then one 
might expect EBV to remain in cells, but under a latent replication program. Thus 
EBV might more effectively harness its transforming capabilities, if EBV is most 
transforming under a latent replication regime. This might result in an increase in 
EBV-associated malignancies among those on a regimen of B cell pathway 
inhibitors for years. 
In the case of genetic disorders affecting B cell signaling, one might 
imagine an activating mutation in a component of the BCR pathway resulting in 
increased EBV titer in a patient’s blood. A recent study on activating mutations of 
PI3Kδ found that two out of nine patients had EBV-associated lymphoma (97). 
This information, when viewed in the light of how readily idelalisib, a PI3Kδ 
inhibitor, blocks BCR-mediated lytic activation, hints at the possibility of BCR 
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pathway modulation as a way to treat EBV-driven B cell malignancies. Therefore, 
a greater understanding of how drugs that affect the B cell pathway affect EBV 
activation may provide useful information to guide new approaches to patient 
care. 
 Other pharmacologic approaches to inhibiting EBV functions have been 
investigated, including the inhibition of EBNA1, an EBV protein present in all 
latently infected. This protein is responsible for EBV genome copying and 
partitioning during latent replication. A group of investigators showed that by 
adding a peptide inhibitor of EBNA1 dimerization, they could force the loss of the 
EBV episome in daughter cells (106, 107).  The peptide had dual functionality, 
not only the inhibition of EBNA1 dimerization but also was fluorescent, which 
readily enabled its visualization in tissue sections. Targeting episomal 
maintenance is a promising tool for treatment in cells that are affected by drugs 
that block lytic activation. Thus an effect similar to depleting the viral reservoir by 










LIST OF ABBREVIATIONS 
AIDS – acquired immunodeficiency syndrome 
BCR – B cell receptor 
BL – Burkitt lymphpma 
BSA – bovine serum albumin 
CsA – cyclosporine A 
CTLA4 – cytotoxic T-lymphocyte-associated protein 4 
DCE – 1,2-dichloroethane 
DCM – dichloromethane 
DMF – dimethylformaldehyde 
DMSO – dimethyl sulfoxide 
EBER – Epstein-barr virus-encoded small RNAs 
EBNA – Epstein-Barr nuclear antigen 
EBV – Epstein-Barr virus 
EDTA – ethylenediaminetetraacetic acid 
FKAM – tacrolimus analog 
FKBP – FK506 binding protein  
FKN4 – tacrolimus analog 
GAPDH – Glyceraldehyde 3-phosphate dehydrogenase 
GFP – green fluorescent protiein 
HEPES – 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HLA – human leukocyte antigen 
Ig – immunoglobulin  
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LCL – lymphoblastoid cell line 
LMP – latent membrane protein 
MACS – magnetic-activated cell sorting 
mTORC1 – mTOR complex 1 
mTORC2 – mTOR complex 2 
NaB – sodium butyrate 
NFAT – nuclear factor of activated T cells 
OKT3 – muromonab-CD3 
PBMC – peripheral blood mononuclear cells 
PBS – phosphate-buffered saline 
PMA – phorbol 12-myristate 13-acetate 
PTLD – post-transplant lymphoproliferative disorder 
SDS-PAGE – sodium dodecyl sulfide polyacrylamide gel electrophoresis 
TAC – tacrolimus 
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